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preventive therapy strategies for patients at intermediate cardiac
risk that need to be tested in a prospective, randomized manner
(4,5).
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Reply
We agree with the comments of Dr. McEvoy and colleagues
regarding our paper (1) that there is an urge to implement coronary
artery calcium (CAC) cutoff scores in clinical practice to enhance
cardiovascular risk stratification in the individual patient. This
especially pertains to persons at intermediate cardiovascular risk, in
whom risk management strategies are least clear. Yet, we do not
think that reporting the absolute CAC score reclassification cutoffs
we would have found by using the classic Framingham Risk Score
instead of our Framingham “refitted” model would be helpful. The
Framingham Risk Score is designed for a population 30 to 74 years
of age (2). Our study focuses on the elderly, of whom a substantial
proportion is older than 75 years of age. Previous research within
the Rotterdam study has pointed out that the Framingham Risk
Score does not fit well in our population (3). Thus, cutoffs derived
in our cohort using the Framingham Risk Score would not be
meaningful.
Of course, in a utopia we would be able to overcome the
inaccuracy of available “general” risk functions. However, we think
it would be helpful to create more tailored risk functions for
populations with specific demographics and/ or presence of car-
diovascular symptoms. Empirically derived cutoffs from these
populations are more likely to apply to the individual patient,
although they should be tested in comparable study populationsbefore they can be safely used in clinical practice. So, despite the
urgent need for CAC cutoffs in cardiovascular risk stratification of
the individual patient, we feel that abundant research still has to be
performed before CAC cutoff scores can safely be used in clinical
practice.
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Nonrandomized Data on
Drug-Eluting Stents Compared
With Coronary Bypass Surgery
Caution With Interpretation
In a recent issue of the Journal, Park et al. (1) presented
long-term follow-up results from the Asan-Multivessel Registry
in which patients are followed after percutaneous coronary
intervention (PCI) with drug-eluting stents (DES) or coronary
artery bypass grafting (CABG) for the treatment of multivessel
coronary artery disease. After 5 years, similar rates of death or
the composite endpoint of death, myocardial infarction, or
stroke were found in the DES and CABG groups. This is the
first paper to compare these groups after such long follow-up,
but it should be highlighted that this is a nonrandomized study.
To date, only the SYNTAX (Synergy Between PCI With
TAXUS and Cardiac Surgery) trial compared patients random-
ized to DES or CABG and after 1 year already showed that
DES failed to reach noninferiority to CABG (2). A possible
explanation for the contradicting results of Park et al. (1) is that
apart from baseline characteristics (age, sex, body mass index)
and comorbid conditions (hypertension, hyperlipidemia, diabe-
tes requiring insulin, heart failure, prior myocardial infarction),
the severity of multivessel disease is less worse than in the
SYNTAX trial (Table 1), with an overall SYNTAX coronary
score that is much lower in the DES group (SYNTAX trial
28.4% vs. 17.4% in the present study). The SYNTAX trial also
included more than twice as many patients with a left main
